# Code Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/code-biotherapeutics

- Industry: Biotechnology
- Headquarters: Hatfield, US
- Website: www.codebiotx.com
- Total disclosed funding: $48M
- Latest round: Series A (May 25, 2022)
- Investors on record: 10

## About

Based in the US, Code Biotherapeutics, Inc. focuses on developing precision genetic medicines using its proprietary 3DNA® platform, addressing critical challenges in genetic therapy delivery.Founded in 2020 and headquartered in Hatfield, US, Code Biotherapeutics, Inc. is dedicated to creating genetic therapies for life-threatening diseases, particularly Duchenne Muscular Dystrophy (DMD). The company has successfully raised funding through two deals, with the most recent being a Series A round on May 25, 2022, where they secured USD 37.5 mn led by Northpond Ventures. Lori Getts, the founder, has a background in biotechnology and has previously established other ventures in the life sciences sector.Code Biotherapeutics specializes in the development of precision genetic medicines, utilizing its innovative 3DNA® platform. This proprietary, multivalent, synthetic DNA delivery system is crafted to tackle significant challenges associated with genetic therapy delivery, such as dose-related toxicity, immunogenicity, and off-target effects. The primary focus is on treating life-threatening diseases, especially DMD, and the company is advancing its internal pipeline to target various genetic disorders within the US healthcare market.Code Biotherapeutics generates revenue through strategic partnerships and collaborations for research and development of its genetic medicine pipeline. This includes agreements with research institutions and pharmaceutical companies that facilitate the development and commercialization of the 3DNA® delivery platform. The partnership structure may involve milestone payments, royalties, or revenue sharing arrangements upon market introduction of their products.In June 2022, Code Biotherapeutics raised USD 37.5 mn in Series A funding, led by Northpond Ventures, with participation from several other investors. The company plans to use this funding to advance DMD and T1D toward IND-enabling studies, expand its pipeline and platform applications, and enhance its manufacturing and operations. The initiatives indicate a commitment to not only innovate new products but also expand their reach within the biotechnology sector.

## Funding rounds

- Series A, May 25, 2022, $38M — New Enterprise Associates, Hatteras Venture Partners, Amgen Ventures, Takeda Ventures, 4BIO Capital Partners, UPMC Enterprises, JDRF T1D Fund, UCB Ventures, Northpond Ventures, CureDuchenne Ventures
- Seed, Mar 2, 2021, $10M — New Enterprise Associates, Takeda Ventures, 4BIO Capital Partners, UPMC Enterprises, JDRF T1D Fund, CureDuchenne Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Seed, Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Seed, Series A
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Seed, Series A
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Seed, Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Seed, Series A
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Seed, Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A